Regencell Bioscience Holdings Limited (RGC) vs Relay Therapeutics, Inc. (RLAY)
A side-by-side comparison of Regencell Bioscience Holdings Limited and Relay Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
RGC
Regencell Bioscience Holdings Limited
$7.76HealthcareDelayed quote: Oct 6, 2026, 3:20 PM EDT
RLAY
Relay Therapeutics, Inc.
$18.37HealthcareDelayed quote: Oct 6, 2026, 3:20 PM EDT
Total return — RGC vs RLAY
growth of $100 · dividends reinvested · last 5yRGC +2520.2% (+92.2%/yr)RLAY -41.8% (-10.3%/yr)RGC compounded faster over this window
Log scale — wide-divergence pair
RGC RLAY
RGC vs RLAY: by the numbers
- •RLAY is the larger company ($4.02B vs $3.84B market cap).
- •Both run net losses; RGC's is the smaller (0.00% vs -2763.64% net margin).
Metrics side by side
Valuation
| Metric | RGC | RLAY |
|---|---|---|
| P/S ratio | N/A | 388.84 |
| P/B ratio | 3151.10 | 4.52 |
Profitability
| Metric | RGC | RLAY |
|---|---|---|
| Gross margin | 0.00% | 76.83% |
| Operating margin | 0.00% | -1971.59% |
| Net margin | 0.00% | -2763.64% |
| ROE | -73.75% | -32.14% |
| ROIC | -69.75% | -33.87% |
Growth (annualized)
| Metric | RGC | RLAY |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -34.29% |
| Total return CAGR (5Y) | 67.94% | -7.92% |
Frequently asked
- How have RGC and RLAY total returns compared?
- Over the past 5 years, RGC delivered 67.94% and RLAY delivered -7.92% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.